By: Caitlin A. Koppenhaver

Last Action: 3/13/2026 House – Died in Health Professions & Programs Subcommittee House Bill 1429 (2026) – The Florida Senate

Florida’s HB 1429 (and Senate companion SB 1728) is one of the clearest messages to date that Florida is preparing to regulate medical spas offering prescription medications, including weight loss drugs and biological products, under a more formal, pharmacy-adjacent framework. The bills would create the “Medical Spa Prescription Drug Oversight Act” and move certain medical spa operations under direct oversight by the Florida Board of Pharmacy, which would effectively allow the Board or approved third parties to conduct onsite inspections.

The Legislature’s starting point is direct: “The Legislature finds that patients are increasingly turning to medical spas for cosmetic and medical procedures. Many of these medical spas prepare and administer prescription medications intended to be sterile, either compounded or commercially available formulations, with no regulatory oversight by the Board of Pharmacy, which raises significant patient safety concerns”. The bill treats that perceived gap as a regulatory problem that needs to be closed. In other words, Florida is treating the outpatient service line where drugs are marketed, stored, handled, and administered, as part of the regulated prescription drug chain.  Medspas are not currently licensed and certainly not required to have anything like a pharmacy license!

What the bill does

HB 1429 would require each medical spa location that “prepares, handles, stores, administers, dispenses, distributes, or otherwise uses” prescription medication at the facility or in connection with providing services to obtain and maintain a license from the Board of Pharmacy. The definition of “medical spa” is drafted to capture modern wellness and longevity models and explicitly includes weight loss services, botulinum toxin injections, hormone therapies, and parenteral nutrient therapies.

“Medical spa” means any facility or practice that offers medical or health care services and that holds itself out as a facility or practice focused on cosmetic or lifestyle treatments, such as weight loss, wellness, longevity, or cosmetic or aesthetic health care services, including, but not limited to, the preparation, administration, or dispensing of prescription drugs for weight loss; botulinum toxin injections; hormone therapies; or parenteral nutrient therapies. The term does not include a facility or practice that otherwise holds a health care facility license from the state.”

The bill is also not just focused on GLP-1’s, as the bill defines a “Prescription medication” to include any drug, including, but not limited to, finished dosage forms or active ingredients that are subject to, defined in, or described in section. 503(b) of the Federal Food, Drug, and Cosmetic Act (which regulates outsourcing facilities) or in certain provisions of the Florida Pharmacy Practice Act and the Florida Drug and Cosmetic Act. The term also includes “any biological product, except for blood and blood components intended for transfusion or biological products that are also medical devices”. 

The proposal also states that a licensed medical spa is treated as a “dispenser” under federal law and must comply with federal supply chain requirements. That provision is a tell:  the bill is not merely about licensure; it is about importing pharmaceutical supply-chain discipline into the med-spa environment, meaning tighter expectations around sourcing, handling, documentation, and accountability. 

If enacted, failure to obtain a license or comply with any requirements may result in disciplinary action by the Florida Board of Pharmacy,  including, but not limited to, fines, suspension, or revocation of the license. The Florida Board of Pharmacy will also maintain a public database of each medical spa licensed in Florida, which will include at a minimum, the name, address, and license number of each medical spa and the name and license number of the responsible person, who must be physically present at the medspa location “for a sufficient amount of time to perform his or her responsibilities”, which includes confirming compliance with the bill’s requirements.

The bigger picture for the peptide and wellness space

Zooming out, HB 1429/SB 1728 fits a broader pattern of Big Pharma infiltrating the wellness space, especially to suppress compounded GLP competition.  Regulators are increasingly looking beyond the compounding site and focusing on the outpatient endpoint where high-demand therapies, particularly GLP-1 weight loss drugs and other peptide offerings, are marketed and administered.  Even when a pharmacy is the dispenser, the consumer-facing platform (often the medical spa) is where risks tend to surface: how the program is marketed, how intake and payment flow are structured, what happens on-site, and how adverse outcomes are handled. Florida’s approach reflects a growing view that compounding oversight, consumer-facing promotion, and outpatient administration are part of one continuous risk chain.

That’s also why the bill includes a consumer protection enforcement provision that directly implicates common GLP-1 marketing practices. The bill ties certain misrepresentations about prescription medications to Florida’s Deceptive and Unfair Trade Practices Act, including the medical spa “misrepresenting a prescription medication as having”:

• A particular standard, quality, or grade;
• Sponsorship, approval, characteristics, ingredients, uses, or benefits;
• A function similar to a drug approved by the federal Food and Drug Administration; or
• Approval from the federal Food and Drug Administration.

For weight loss programs, that language reads as a warning shot at equivalency-style messaging and FDA-adjacent phrasing. This is also one of the first states we have seen include a focus specifically on marketing, as typically the FDA and FTC will focus on marketing enforcement.  The bill changes the entire character of a medspa to a highly regulated environment and will likely cause many Medspas to rethink their commitment to GLP weight loss programs.  And the bill goes further than that by expanding its pharma net to products like Botox.   Why is that?  Is this going to save lives?  What problem is being fixed here?  The proposed law seeks to regulate with no apparent precision and somewhat brutalizing an entire industry. 

Comments to Common Questions

Likelihood of passage

It’s too early in the 2026 session to speak in certainties, but the bill is moving in both chambers with companion legislation. Companion bills filed early and routed through committee are often a sign the concept has meaningful traction, even if details evolve through amendments and stakeholder input.  Where exactly are the stakeholders in this process?  Has any Medspa at all been consulted re the presumptions riddled through this bill?

Timing/effective date

If passed, SB 1728 lists an effective date of July 1, 2026, while HB 1429 is drafted to take effect upon becoming law.  There is not reasonable opportunity to prepare to even to get rid of perhaps a large supply of affected product.  HB 1429 also directs the Board to adopt implementing rules within six months after the section takes effect, which suggests a buildout period for the application process and enforcement infrastructure. The practical takeaway is that the “real” compliance protocols will likely be driven by how quickly the Board stands up rules and applications, but businesses should plan as if expectations could move quickly once enacted.

Licensing Implications

The core mechanism is a new Board of Pharmacy license requirement for medical spas that handle prescription medications as described in the trigger language. The bill also contemplates a public database of licensed medical spas and the designated “responsible person,” which reinforces that Florida intends visibility and accountability at the facility level, not just a get it and forget it registration.

Proactive steps

While the bill is still proposed, the most efficient preparation is internal clarity. Medspas should review the bill closely and confirm whether the current workflow triggers licensure based on how prescription products are sourced, stored, and administered at the facility or “in connection with” services, and pressure-test marketing and patient-facing materials for any equivalency or FDA-adjacent messaging that could create exposure under the consumer protection provision. 

Bottom line

As we previously reported about Indiana’s medspa bill introduced in January, HB 1429/SB 1728 is Florida’s attempt to regulate medical spas offering prescription medications—particularly in consumer-facing wellness and weight loss models—by treating those settings as part of the prescription drug oversight ecosystem. If you’re operating in the GLP-1/weight loss lane, this is a bill to watch closely, because it targets the delivery model—not just the drug.  Cast in its worst light, any business that utilizes a product that compete with Pharma GLPs can expect similar overregulation and disregard for rational or demonstrable justification. 

By: Caitlin A. Koppenhaver

If you felt like the compounded oral semaglutide headlines were changing by the hour, you weren’t imagining it. Within days, the narrative shifted from a consumer-facing launch to heightened FDA attention and legal escalation, ending with a rapid withdrawal.

How This Unfolded—Fast

On Thursday, February 5, Hims & Hers announced it was expanding its weight-loss portfolio with access to compounded semaglutide pills, promoted as having “the same active ingredient as Wegovy®”, and marketed with introductory pricing starting at $49 (with pricing that varies by plan). The announcement immediately landed in the middle of the broader “compounded GLP-1” conversation, namely, whether these offerings fit within narrow, patient-specific compounding exceptions permitted under the Federal Food, Drug, and Cosmetic Act (FDCA), or whether they were being positioned as scaled substitutes for FDA-approved products, which is where FDA scrutiny and branded manufacturer enforcement tend to converge.

That same day, Novo Nordisk’s CEO publicly questioned whether a compounded oral semaglutide pill would work as consumers expect, reportedly describing it as a “waste of money” because it lacks the SNAC absorption technology used in Novo’s FDA-approved oral Wegovy formulation. “SNAC” is a proprietary excipient that helps semaglutide survive the stomach and be absorbed into the bloodstream when taken orally. Without it, semaglutide is largely degraded by stomach acid and enzymes, meaning the active peptide may not reach the bloodstream in meaningful amounts. Novo’s point,  anchored in its public comments at an investor meeting on Feb. 5, 2026, is that an oral semaglutide pill without this type of enhancer is unlikely to perform clinically like an FDA-approved product.

By Friday, February 6, the FDA publicly escalated its position. In a formal statement, the agency said it intends to “take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs”. The action was framed around consumer protection and the agency’s inability to verify quality, safety, or efficacy for compounded formulations. 

The business impact was almost immediate. On Saturday, February 7, reporting confirmed Hims stopped offering access to the compounded semaglutide pill after what it described as “constructive conversations with stakeholders across the industry”, in the wake of FDA’s statements and the broader regulatory scrutiny.

And on Monday, February 9, Novo Nordisk formally escalated to litigation, filing suit against Hims & Hers alleging patent infringement tied to compounded semaglutide products and seeking injunctive relief and damages. As stated by their CEO, “Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages”.

One point worth flagging, because it helps explain the speed of the escalation, is how Novo framed the moment. In public comments, Novo suggested Hims was the “tipping point,” in the sense that a highly visible, consumer-facing rollout drew immediate attention and prompted a faster, more public response. 

What This Means for Industry Participants

While this week in no way settled the compounded GLP-1 debate, it did, however, show how quickly the conversation can accelerate when FDA signaling and branded manufacturer enforcement converge in a high-demand category. It also highlights a few practical realities compounding pharmacies and their partners should keep in mind right now.

For compounders, the risk often turns on posture and messaging: tightly patient-specific, pharmacy-controlled dispensing tends to be viewed differently than marketing that reads like a substitute for an FDA-approved drug.

For telehealth platforms, scale and consumer marketing amplify everything. Even if a licensed pharmacy is dispensing, a national rollout can draw immediate attention from regulators and brand manufacturers.

And for both, transparency matters, not just from an FDA standpoint. From an FTC risk standpoint, regulators look at the overall takeaway a reasonable consumer would get from the ad, not just whether each sentence is technically defensible. If the headline, pricing, visuals, or phrasing leaves consumers thinking “FDA-approved” or “equivalent to Wegovy,” disclaimers buried later may not cure the overall net impression.